ImmuneOncia Therapeutics, Inc. Logo

ImmuneOncia Therapeutics, Inc.

A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.

424870 | KO

Overview

Corporate Details

ISIN(s):
KR7424870004
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 탑실로35번길 25, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ImmuneOncia Therapeutics, Inc. is a clinical-stage, immuno-oncology-centric biopharmaceutical company dedicated to developing cutting-edge immunotherapies for cancer treatment. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company leverages expertise in drug development and antibody engineering. ImmuneOncia's pipeline focuses on developing immune checkpoint inhibitors targeting T cells and macrophages. Its portfolio includes IMC-001, its lead candidate, and IMC-002, a fully human anti-CD47 monoclonal antibody for various cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 887.8 KB
2025-05-30 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 43.9 KB
2025-05-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 102.9 KB
2025-05-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-12 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 323.5 KB
2025-04-30 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 525.5 KB
2025-04-30 00:00
Prospectus
[기재정정]투자설명서
Korean 3.9 MB
2025-04-28 00:00
Prospectus
투자설명서
Korean 3.3 MB
2025-04-18 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.4 MB
2025-04-17 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 4.2 MB
2025-04-04 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.9 MB
2025-04-02 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.5 MB
2025-03-28 00:00
Annual / Quarterly Financial Statement
감사보고서 (2024.12)
Korean 397.2 KB
2025-03-14 00:00
Registration Form
증권신고서(지분증권)
Korean 3.1 MB
2024-04-08 00:00
Annual / Quarterly Financial Statement
감사보고서 (2023.12)
Korean 355.7 KB

Automate Your Workflow. Get a real-time feed of all ImmuneOncia Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ImmuneOncia Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ImmuneOncia Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Inventiva S.A. Logo
Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.
United States of America
IVA
Invivyd, Inc. Logo
Develops evolution-resistant antibodies to protect against viral diseases like COVID-19 and flu.
United States of America
IVVD
IO Biotech, Inc. Logo
Develops dual-action, off-the-shelf therapeutic cancer vaccines for solid tumors.
United States of America
IOBT
IONIS PHARMACEUTICALS INC Logo
A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.
United States of America
IONS
IOVANCE BIOTHERAPEUTICS, INC. Logo
Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.
United States of America
IOVA
Ipsen Logo
Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.
France
IPN
IRLAB Therapeutics Logo
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden
IRLAB
IRONWOOD PHARMACEUTICALS INC Logo
Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.
United States of America
IRWD
ISU Abxis Co., Ltd. Logo
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea
086890
Iterum Therapeutics plc Logo
Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.
United States of America
ITRM

Talk to a Data Expert

Have a question? We'll get back to you promptly.